¼º¼®ÁÖ
¼Ò
¼Ó
: °³²Â÷º´¿ø
Àü¹®ºÐ¾ß : ºÎÀξÏ, ÀڱñÙÁ¾, ³¼ÒÁ¾¾ç,·Îº¿¼ö¼ú, º¹°°æ,Àڱðæ, ´ÜÀÏ°ø¼ö¼ú
Á÷
ˤ
: ±³¼ö
¸Þ
ÀÏ
:
.
Àü
È
:
02.3468.3000
ÆÑ
½º
:
02.558.1119
ÁÖ
¼Ò
:
¼¿ï½Ã °³²±¸ ¿ª»ï1µ¿ 650-9
ȨÆäÀÌÁö:
ÅǸ޴º
ÁÖ¿ä¹ßÇ¥³í¹®
¹øÈ£
±¸ºÐ
Á¦¸ñ
´Ù¿î·Îµå
84
ÇØ¿Ü
Use of Complex Surgical Procedures, Patterns of Tumor Spread, and CA-125 Predict a Risk of Incomplete Cytoreduction: A Korean Gynecologic Oncology Group Study (KGOG-3022).
83
ÇØ¿Ü
Laparoendoscopic single-site versus conventional laparoscopic gynecologic surgery: a meta-analysis of randomized controlled trials.
82
ÇØ¿Ü
Would fewer port numbers in laparoscopy produce better cosmesis?: A prospective study.
81
ÇØ¿Ü
Comparison of dilatation & curettage and endometrial aspiration biopsy accuracy in patients treated with high-dose oral progestin plus levonorgestrel intrauterine system for early-stage endometrial cancer.
80
ÇØ¿Ü
Combined Medroxyprogesterone Acetate (MPA)/Levonorgestrel-intrauterine system (LNG-IUS) treatment in young women with early-stage endometrial cancer.
79
ÇØ¿Ü
Comparison of Single-Port, Two-Port and Four-Port Laparoscopic Surgery for Cyst Enucleation in Benign Ovarian Cysts.
78
ÇØ¿Ü
Torsion of parasitic myoma in the mesentery after myomectomy.
77
ÇØ¿Ü
LNG-IUS treatment of non-atypical endometrial hyperplasia: Can Pipelle endometrial sampling be an accurate method of follow-up evaluation?
76
ÇØ¿Ü
Progestin re-treatment in patients with recurrent endometrial adenocarcinoma after successful fertility-sparing management using progestin.
75
±¹³»
Clinical applications of levonorgestrel-releasing intrauterine system to gynecologic diseases.
1
2
3
4
5
6
7
8
9
10
Copyright ¨Ï chamc, All rights reserved.
ºü¸£°í Æí¸®ÇÑ ÀÎÅÍ³Ý Áø·á¿¹¾à
Àüȹ®ÀÇ
°³²Â÷º´¿ø 02.3468.3000
ºÐ´çÂ÷º´¿ø 031.780.5000
Â÷¿ò 02.3015.5300
±¸¹ÌÂ÷º´¿ø 054.450.9700
´ë±¸¿©¼ºÂ÷º´¿ø 02.222.4200
°³²°ÇÁø¼¾ÅÍ 02.2191.3900
ºÐ´çÁ¾ÇÕ°Ç°ÁõÁø¼¾ÅÍ 031.780.5940
½ºÆ÷·º½º °ÇÁø¼¾ÅÍ 02.3473.2111
±¸¹ÌÂ÷º´¿ø°ÇÁø¼¾ÅÍ 054.450.9800
ȨÆäÀÌÁö°ü¸®ÀÚ 031.780.1729